Trial Profile
Phase II, Randomized, Open Label to Evaluate Efficacy,Safety of Radium 223 in Prolonging the Off Treatment Interval in Men With Rising PSA Post-rad, or Post-prostatectomy Without Bone Mets on Intermittent Androgen Ablation Therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms RAND
- 13 Oct 2016 Status changed from discontinued to withdrawn prior to enrolment.
- 13 Oct 2016 Status changed from recruiting to discontinued.
- 28 Jan 2016 New trial record